MedTrace Logo

A Randomized Double-blind Trial With 6 Antipsychotic Drugs for Schizophrenia

NCT02192723 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 550

Last updated 2016-07-12

No results posted yet for this study

Summary

The purpose of this study is to compare the efficacy and side effects of 6 commonly used antipsychotic drugs in the treatment of schizophrenia in a Chinese population.

Conditions

Interventions

DRUG

Typical antipsychotic

Haloperidol (6\~20mg/day) and perphenazine (16\~64mg/day), twice per day, 8 weeks

DRUG

Risperidone

2\~6mg/day, twice per day, 8 weeks

DRUG

Olanzapine

Olanzapine, 400\~750mg/day, twice per day, 8 weeks

DRUG

Quetiapine

Quetiapine, 400～750mg/day, twice per day, 8 weeks

DEVICE

Aripiprazole

Aripiprazole, 10～30mg/day, twice per day, 8 weeks

DRUG

Ziprasidone

Ziprasidone 80\~160mg/day, twice per day, 8 weeks

Sponsors & Collaborators

  • Beijing HuiLongGuan Hospital

    lead OTHER

Principal Investigators

  • Zhi-Ren Wang, MD, PhD · Beijing HuiLongGuan Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-06-30
Primary Completion
2014-06-30
Completion
2014-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02192723 on ClinicalTrials.gov